Megan May, PharmD, BCOP, FHOPA, FAPO

This OPC interview discusses practice-changing updates from ASCO and EHA, including advances in bispecific antibodies, breast cancer treatment strategies, and multiple myeloma sequencing considerations.

Experts discuss real-world BTCE challenges, toxicity monitoring, and evolving pharmacy practice.

Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses lurbinectedin and tarlatamab and what ongoing research in the small cell lung cancer (SCLC) space entails.

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.